Study cohort | Study setting | |
---|---|---|
Inclusion | Exclusion | |
PROVALID | ▪ Aged 18–75 years ▪ Incident or prevalent DM2 with/without CKD | • Active malignancy requiring chemotherapy |
GCKD | ▪ Aged 18–74 years ▪ Caucasian ethnicity ▪ eGFR: 30–60 mL/min/1.73m2with or without urinary albumin excretion ▪ eGFR > 60 mL/min/1.73m2 - Albumin excretion of > 300mg/g creatinine - Proteinuria > 500mg/day | ▪ Active malignancy in the 24 months prior to inclusion ▪ Renal or other transplantations ▪ NYHA IV heart failure |
DIACORE | ▪ Aged ≥ 18 years ▪ Caucasian ethnicity ▪ Prevalent DM2 | ▪ On chronic renal replacement therapy ▪ Active malignancy ▪ Pregnancy ▪ Further diseases and infections |